MSK 2020 Update on the Treatment of Pituitary Tumors: Emerging Therapies
MSK 2020 Update on the Treatment of Pituitary Tumors: Emerging Therapies is organized by Memorial Sloan Kettering Cancer Center (MSKCC) and will be held on May 29, 2020 at Mortimer B. Zuckerman Research Center, New York City, New York, United States of America.
This course is intended for endocrinologists, neurosurgeons, otolaryngologists, radiation oncologists, neurologists, ophthalmologists, neuro-oncologists, family medicine and internal medicine physicians, physicians in training and other allied health professionals who treat and manage patients with pituitary diseases. We also invite patients with pituitary disease and their caregivers to attend this educational activity and participate in our interactive afternoon breakout sessions.
After completion of this didactic and case-based educational activity, participants will be up to date on the latest developments in ongoing basic and translational science as well as the clinical management of patients with pituitary conditions.
After completion of this didactic and case-based educational activity, participants will be up to date on the latest developments in ongoing basic and translational science as well as the clinical management of patients with pituitary conditions. Participants will be able to:
• Review available and emerging medical therapies for Cushing’s and acromegaly
• Discuss new therapies for aggressive and malignant tumors
• Understand decision making involved in surgical intervention for pituitary tumors
• Get an overview on potential surgical complications
• Describe the role of radiation therapy for pituitary tumors
• Review neuro-ophthalmological findings in pituitary disease risks
• Discuss treatment of immunotherapy-related pituitary dysfunction
• Assess advances in neuroimaging and tumor markers that may predict tumor behavior and clinical outcomes
Overall this course aims to improve patient care and outcomes through evidence-based discussion of clinical practice guidelines and emerging therapies. Our goal is to assess and update current practices to promote earlier diagnosis and treatment of pituitary diseases. The multidisciplinary nature of the course will allow for dissemination of knowledge across the variety of practitioners caring for pituitary patients, and for the patients themselves.
Request for Case Submissions (Provider/Clinical Breakout Session):
There will be a tumor board during the provider/clinical breakout session where attendees and faculty will review cases. Attendees will have an opportunity to submit a case for discussion during the course at registration. In order to prepare your submission, we ask that you provide a BRIEF summary of your case and include key lab results. Please ensure that all identifiable PHI has been removed. Cases should have an educational purpose. The course faculty will not be able to provide a detailed/complex consult review during the course and they will try to get through as many cases as possible.
Patient Breakout Session:
We also invite patients with pituitary disease and their caregivers to attend this educational activity and participate in our interactive afternoon breakout sessions. Pituitary patients will be able to review treatment options, learn about ongoing clinical trials, and discuss their comprehensive care with providers and other patients. The educational objective of this patient session is to provide a forum for pituitary patients to discuss treatment options and new therapies with providers and other patients.
MSK is pleased to invite patients and caregivers to attend this course on a complimentary basis. If you are a patient or caregiver interested in attending, please email firstname.lastname@example.org to register (registration is required in order to attend).
Live Simulcast Available:
We are pleased to offer a live simulcast option for this course. CME credit is offered for the live simulcast and active participation is required throughout the course. We do hope you will attend in person but understand that can sometimes be a challenge, so we are happy to offer the live simulcast as an option. Registration for the simulcast is required; please select the "Live Simulcast" option during course registration. A link to view the Symposium will be emailed to you the day before the course begins.
Please note that the simulcast will only be offered for the Provider/Clinical Track of this program.
• Review the efficacy and side effect profiles of treatment options, including emerging therapies, for Cushing’s and acromegaly
• Discuss surgical outcomes and risk management for pituitary and skull base tumors
• Describe recent advances in pituitary neuropathology and neuroimaging
• Critically appraise the role of radiation therapy in the management of pituitary tumors
• Debate treatment decisions supporting the use and timing of new therapies for aggressive and malignant pituitary tumors
• Provide a forum for pituitary patients to discuss treatment options and new therapies with providers and other patients
|Contact No. :||646-227-2025
|Registration Type||Last Date||Price|
|Physicians (MDs, PhDs, and DOs) Early Fee||27 Mar,2020||USD 175.00|
|Residents, Fellows, Advanced Practice Providers, Nurses and Other Healthcare Providers Early Fee||27 Mar,2020||USD 125.00|
|Industry Professionals Conference Fee||29 May,2020||USD 395.00|
|Live Simulcast Conference Fee||29 May,2020||USD 425.00|